secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2026-06-01T12:30:30+00:00
Accession:  0001104659-26-068615
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Oncology annual meeting results: directors elected, equity plan approved, option repricing narrowly passes
--------------------------------------------------------------------------------

- Class III directors Dennis M. Lanfear and Mats L. Wahlström re-elected with 82.5M and 81.2M votes for each, respectively.
- Ratification of Ernst & Young as independent auditor approved by 121.1M votes for, 1.5M against.
- Say-on-pay advisory vote on executive compensation passed with 73.3M for, 10.9M against, 4.8M abstain.
- Stock option repricing proposal (Prop 4) approved in close vote: 46.0M for, 45.4M against, 0.4M abstain.
- Increase in shares reserved under Amended 2014 Equity Plan approved: 59.5M for, 24.9M against, 4.6M abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926068615/0001104659-26-068615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926068615/chrs-20260527x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-068615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer